Clinical trials: Edematous
Fluid Overload
Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients
A reasonable and simple algorithm was used to guide the dry weight determination with Body Composition Monitor with the principle of Bioimpedance Spectroscopy (BCM-BIS) and analyze the feasibility of this algorithm and evaluate…
- Trial name
- NCT02325856
- Testing
- Bioimpedance Spectroscopy, Clinical judgement
- Volunteers
- 298 people
- Sponsor
- An Hsin QingShui Clinic
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination…
- Trial name
- AMARONE (NCT05919693)
- Testing
- Remigromig
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Edematous Fibrosclerotic Panniculopathy, Cellulite
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium…
- Trial name
- APHRODITE (NCT05419505)
- Testing
- CCH-aaes, Antifibrinolytic Agent
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cirrhosis
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics…
- Trial name
- NCT01114828
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Diabetic Macular Edema
Ranibizumab and Bevacizumab for Diabetic Macular Edema
Background: Diabetic macular edema is a common eye complication of diabetes. It causes the blood vessels in the retina at the back of the eye to leak, causing swelling.
- Trial name
- NCT01610557
- Testing
- Ranibizumab, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- National Eye Institute (NEI)
Meniere's Disease
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
- Trial name
- NCT02603081
- Testing
- SPI-1005
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Acute Kidney Injury, Fluid Overload
Restrictive Versus Liberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury
Critically ill patients with acute kidney injury and fluid overload who are frequently treated by fluid removal during dialysis are at an increased risk of complications and death.
- Conditions
- Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications
- Trial name
- RELIEVE-AKI (NCT05306964)
- Testing
- Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Pittsburgh
Diabetic Macular Edema
Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Currently, two similar medications are available for injection into the eye to treat a variety of eye diseases. These medications are called ranibizumab (Lucentis) and bevacizumab (Avastin).
- Trial name
- NCT01661946
- Testing
- Bevacizumab, Ranibizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Queen's University
Diabetic Macular Edema
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema.
- Trial name
- DIME (NCT02471651)
- Testing
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Fluid Overload, Anesthesia; Adverse Effect, Spinal and Epidural
Can Vena Cava Ultrasound Guided Volume Repletion Prevent Spinal Induced Significant Hypotension in Elective Patients?
Aim of this study is to determine whether Inferior Vena Cava analyzed by trans-thoracic echocardiography is an effective method to guide titrated fluid repletion in non critical patients, in order both to decrease post procedural…
- Conditions
- Fluid Overload, Anesthesia; Adverse Effect, Spinal and Epidural, Regional Anesthesia Morbidity
- Trial name
- NCT02271477
- Testing
- Ultrasound-guided volemic repletion
- Where
- Switzerland
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Diabetic Macular Edema
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
This study is being conducted to assess the effects of topical nonsteroidal anti-inflammatories (NSAIDs) on macular retinal volume compared with placebo in eyes with non-central diabetic macular edema (DME).
- Trial name
- NCT01331005
- Testing
- nepafenac 0.1% drops, Nepafenac Vehicle
- Where
- 32 sites in United States
- Volunteers
- 125 people
- Sponsor
- Jaeb Center for Health Research
Heart Failure, Fluid Overload
Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
This study aims to compare the pharmacokinetics and pharmacodynamics of subcutaneous (SC) and intravenous (IV) furosemide. The test formulation in this study is furosemide injection, 80 mg/1 mL, buffered to a neutral pH for SC…
- Trial name
- NCT06167707
- Testing
- SCP-111, Furosemide USP
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- scPharmaceuticals, Inc.
Corneal Disease, Fuch's Dystrophy
Cornea Donor Study
The Cornea Donor Study (CDS) was designed as a prospective cohort study with the following objectives: To determine whether the graft-failure rate over a 5-year follow-up period following corneal transplantation is the same when…
- Conditions
- Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
- Trial name
- CDS (NCT00006411)
- Testing
- corneas assigned by donor age group
- Where
- United States
- Volunteers
- 1,090 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusions
Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
Comparative study to see if treating with Osurdex in addition to Avastin in patients with retinal vein occlusions helps increased visual acuity outcomes
- Trial name
- NCT01085734
- Testing
- Avastin, Osurdex
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Maturi, Raj K., M.D., P.C.
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women
Subjects will be screened for study eligibility within 14 days prior to enrolling in this study. Subjects with 2 treatment areas (bilateral buttocks) with moderate or severe levels of cellulite as independently assessed by the…
- Trial name
- RELEASE-2 (NCT03446781)
- Testing
- EN3835
- Where
- 25 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acute Cerebrovascular Accident, Cerebral Edema
Histamine Glutamate Antagonism in Stroke
Stroke is the 4th leading cause of death in United States with an estimated 1 death every 4 minutes. On average, someone suffers from stroke in United States every 40th second. Stroke recurs in 1 out of 4 stroke patients.
- Trial name
- NCT02142712
- Testing
- Diphenhydramine, Pantoprazole, Famotidine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida